{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:50:57Z","timestamp":1790610657016,"version":"4.1.0"},"reference-count":150,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Agents Cancer"],"DOI":"10.1186\/s13027-026-00764-5","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:35:30Z","timestamp":1777368930000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Regulation of immune tolerance in hepatocellular carcinoma by liver diseases: a review"],"prefix":"10.1186","volume":"21","author":[{"given":"Jinyi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanda","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"issue":"3","key":"764_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"764_CR2","doi-asserted-by":"publisher","first-page":"e100148","DOI":"10.1136\/egastro-2024-100148","volume":"3","author":"T Hu","year":"2025","unstructured":"Hu T, Wang S, Wang Y, Wang X, Shang L, Wang K. Burden of digestive system malignancies and its impact on life expectancy in China, 2004\u20132021. eGastroenterology. 2025;3(2):e100148.","journal-title":"eGastroenterology"},{"key":"764_CR3","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1146\/annurev-med-042220-021121","volume":"73","author":"RC Sperandio","year":"2022","unstructured":"Sperandio RC, Pestana RC, Miyamura BV, Kaseb AO. Hepatocellular Carcinoma Immunotherapy. Annu Rev Med. 2022;73:267\u201378.","journal-title":"Annu Rev Med"},{"key":"764_CR4","first-page":"48","volume":"8","author":"Y Chen","year":"2025","unstructured":"Chen Y, Chen D, Liang Z, Yu H, Sun H, Hu Y, et al. Immune checkpoint inhibitors in hepatocellular carcinoma therapy: resistance mechanisms, liver transplantation challenges and management strategies. Cancer Drug Resist. 2025;8:48.","journal-title":"Cancer Drug Resist"},{"key":"764_CR5","doi-asserted-by":"crossref","unstructured":"Dai XY, Yang XJ, Wu H, Lv YH, Lan T. Mechanisms of immune checkpoint inhibitor resistance in hepatocellular carcinoma and strategies for reversal. Cancers (Basel). 2025;18(1).","DOI":"10.3390\/cancers18010039"},{"issue":"1","key":"764_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13045-025-01739-6","volume":"18","author":"S Dai","year":"2025","unstructured":"Dai S, Chen Y, Cai W, Dong S, Zhao J, Chen L, et al. Combination immunotherapy in hepatocellular carcinoma: synergies among immune checkpoints, TKIs, and chemotherapy. J Hematol Oncol. 2025;18(1):85.","journal-title":"J Hematol Oncol"},{"issue":"7964","key":"764_CR7","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41586-023-06114-4","volume":"618","author":"G Wang","year":"2023","unstructured":"Wang G, Li J, Bojmar L, Chen H, Li Z, Tobias GC, et al. Tumour extracellular vesicles and particles induce liver metabolic dysfunction. Nature. 2023;618(7964):374\u201382.","journal-title":"Nature"},{"key":"764_CR8","doi-asserted-by":"publisher","first-page":"1133308","DOI":"10.3389\/fimmu.2023.1133308","volume":"14","author":"C Chen","year":"2023","unstructured":"Chen C, Wang Z, Ding Y, Qin Y. Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma. Front Immunol. 2023;14:1133308.","journal-title":"Front Immunol"},{"key":"764_CR9","doi-asserted-by":"publisher","first-page":"101736","DOI":"10.1016\/j.smim.2023.101736","volume":"66","author":"T Cramer","year":"2023","unstructured":"Cramer T. Impact of dietary carbohydrate restriction on the pathobiology of Hepatocellular Carcinoma: The gut-liver axis and beyond. Semin Immunol. 2023;66:101736.","journal-title":"Semin Immunol"},{"issue":"6","key":"764_CR10","doi-asserted-by":"publisher","first-page":"167230","DOI":"10.1016\/j.bbadis.2024.167230","volume":"1870","author":"X Liu","year":"2024","unstructured":"Liu X, Li S, Wang L, Ma K. Microecological regulation in HCC therapy: Gut microbiome enhances ICI treatment. Biochim Biophys Acta Mol Basis Dis. 2024;1870(6):167230.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"3","key":"764_CR11","doi-asserted-by":"publisher","first-page":"e71044","DOI":"10.1111\/jcmm.71044","volume":"30","author":"K Nouri","year":"2026","unstructured":"Nouri K, Asadollahei N, Haghir-Sharif-Zamini Y, Seydi H, Salehi M, Mesdaghi M, et al. T Cell Exhaustion in Hepatocellular Carcinoma: A Substantial Barrier in Immunotherapy. J Cell Mol Med. 2026;30(3):e71044.","journal-title":"J Cell Mol Med"},{"issue":"5","key":"764_CR12","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.jhep.2025.06.007","volume":"83","author":"E Jaeckel","year":"2025","unstructured":"Jaeckel E, Friedman SL, Hudecek M, Protzer U. Chimeric antigen receptor (CAR) T-cell therapy: Engineering immune cells to treat liver diseases. J Hepatol. 2025;83(5):1156\u201371.","journal-title":"J Hepatol"},{"key":"764_CR13","doi-asserted-by":"crossref","unstructured":"Ou Y, Wei H, Peng C, Li J, Wei K, Zhan C, et al. Overcoming MDSC-mediated immunosuppression in hepatocellular carcinoma: from mechanisms to novel immunotherapeutic approaches. Cancers (Basel). 2026;18(6).","DOI":"10.3390\/cancers18060980"},{"issue":"1","key":"764_CR14","doi-asserted-by":"publisher","first-page":"101384","DOI":"10.1016\/j.jpha.2025.101384","volume":"16","author":"T Zhang","year":"2026","unstructured":"Zhang T, Zhao X, Gao T, Ma F. Tumor-associated macrophages in hepatocellular carcinoma: Cellular plasticity and therapy resistance in crosstalk. J Pharm Anal. 2026;16(1):101384.","journal-title":"J Pharm Anal"},{"key":"764_CR15","doi-asserted-by":"publisher","first-page":"105234","DOI":"10.1016\/j.critrevonc.2026.105234","volume":"222","author":"M Chen","year":"2026","unstructured":"Chen M, Wang W, Jie D, Gu L. Interplay between exosomes and the PD-1\/PD-L1 axis in hepatocellular carcinoma: Implications for immune escape and immunotherapy. Crit Rev Oncol Hematol. 2026;222:105234.","journal-title":"Crit Rev Oncol Hematol"},{"key":"764_CR16","doi-asserted-by":"crossref","unstructured":"Xie W, Fang J, Wang Z, Li X, Du J, Ling C. Pleiotropic mechanisms of cancer-associated fibroblast-mediated resistance in hepatocellular carcinoma: emerging therapeutic vulnerabilities and targeting strategies. Cancer Gene Ther. 2026.","DOI":"10.1038\/s41417-026-01007-w"},{"issue":"3","key":"764_CR17","doi-asserted-by":"publisher","first-page":"e100218","DOI":"10.1136\/egastro-2025-100218","volume":"3","author":"Z Yang","year":"2025","unstructured":"Yang Z, Liu Z, Liu W, Dong XC. Steatotic liver disease and cancer: from pathogenesis to therapeutic targets. eGastroenterology. 2025;3(3):e100218.","journal-title":"eGastroenterology"},{"issue":"1","key":"764_CR18","doi-asserted-by":"publisher","first-page":"e312","DOI":"10.71321\/e37ss652","volume":"2","author":"I Karsidag","year":"2025","unstructured":"Karsidag I, Liu H. The Recent Changing Global Landscape of Cancer. Life Conflux. 2025;2(1):e312.","journal-title":"Life Conflux"},{"issue":"6","key":"764_CR19","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1007\/s10620-021-07048-5","volume":"67","author":"K Pinyopornpanish","year":"2022","unstructured":"Pinyopornpanish K, Al-Yaman W, Dasarathy S, Romero-Marrero C, McCullough A. Hepatocellular Carcinoma in Patients Without Cirrhosis: The Fibrosis Stage Distribution, Characteristics and Survival. Dig Dis Sci. 2022;67(6):2677\u201387.","journal-title":"Dig Dis Sci"},{"issue":"1","key":"764_CR20","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/HEP.0000000000000270","volume":"78","author":"A Guillot","year":"2023","unstructured":"Guillot A, Winkler M, Silva Afonso M, Aggarwal A, Lopez D, Berger H, et al. Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression. Hepatology. 2023;78(1):150\u201366.","journal-title":"Hepatology"},{"issue":"2","key":"764_CR21","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.dld.2024.09.006","volume":"57","author":"BS Hofer","year":"2025","unstructured":"Hofer BS, Simbrunner B, K\u00f6nigshofer P, Brusilovskaya K, Petrenko O, Taru V, et al. Aetiology-specific inflammation patterns in patients and rat models of compensated cirrhosis. Dig Liver Dis. 2025;57(2):450\u20138.","journal-title":"Dig Liver Dis"},{"key":"764_CR22","doi-asserted-by":"crossref","unstructured":"Paik JM, Henry L, Younossi Y, Ong J, Alqahtani S, Younossi ZM. The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019. Hepatol Commun. 2023;7(10).","DOI":"10.1097\/HC9.0000000000000251"},{"key":"764_CR23","doi-asserted-by":"crossref","unstructured":"Cheu JW, Wong CC. The immune microenvironment of steatotic hepatocellular carcinoma: current findings and future prospects. Hepatol Commun. 2024;8(9).","DOI":"10.1097\/HC9.0000000000000516"},{"issue":"2","key":"764_CR24","doi-asserted-by":"publisher","first-page":"e065","DOI":"10.1097\/AS9.0000000000000065","volume":"2","author":"M Molinari","year":"2021","unstructured":"Molinari M, Kaltenmeier C, Samra PB, Liu H, Wessel C, Lou Klem M, et al. Hepatic Resection for Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of 7226 Patients. Ann Surg Open. 2021;2(2):e065.","journal-title":"Ann Surg Open"},{"issue":"7854","key":"764_CR25","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","volume":"592","author":"D Pfister","year":"2021","unstructured":"Pfister D, N\u00fa\u00f1ez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592(7854):450\u20136.","journal-title":"Nature"},{"issue":"3","key":"764_CR26","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1097\/HEP.0000000000000591","volume":"79","author":"M Li","year":"2024","unstructured":"Li M, Wang L, Cong L, Wong CC, Zhang X, Chen H, et al. Spatial proteomics of immune microenvironment in nonalcoholic steatohepatitis-associated hepatocellular carcinoma. Hepatology. 2024;79(3):560\u201374.","journal-title":"Hepatology"},{"issue":"14","key":"764_CR27","doi-asserted-by":"publisher","first-page":"6025","DOI":"10.7150\/ijbs.120657","volume":"21","author":"J Zhao","year":"2025","unstructured":"Zhao J, Zhang Y, Wei Z, Li K, Sun L, Li D, et al. The PI3K\/Akt\/mTOR Pathway: Immuno-Metabolic Orchestration in IR\/MASH-Associated Hepatocellular Carcinoma. Int J Biol Sci. 2025;21(14):6025\u201341.","journal-title":"Int J Biol Sci"},{"issue":"9","key":"764_CR28","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.cmet.2022.07.010","volume":"34","author":"P Zhang","year":"2022","unstructured":"Zhang P, Chen Z, Kuang H, Liu T, Zhu J, Zhou L, et al. Neuregulin 4 suppresses NASH-HCC development by restraining tumor-prone liver microenvironment. Cell Metab. 2022;34(9):1359\u2013e767.","journal-title":"Cell Metab"},{"issue":"1","key":"764_CR29","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12964-024-01489-x","volume":"22","author":"Y Liu","year":"2024","unstructured":"Liu Y, Chen H, Yan X, Zhang J, Deng Z, Huang M, et al. MyD88 in myofibroblasts enhances nonalcoholic fatty liver disease-related hepatocarcinogenesis via promoting macrophage M2 polarization. Cell Commun Signal. 2024;22(1):86.","journal-title":"Cell Commun Signal"},{"issue":"5","key":"764_CR30","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.jhep.2023.06.021","volume":"79","author":"L Wang","year":"2023","unstructured":"Wang L, Zhu L, Liang C, Huang X, Liu Z, Huo J, et al. Targeting N6-methyladenosine reader YTHDF1 with siRNA boosts antitumor immunity in NASH-HCC by inhibiting EZH2-IL-6 axis. J Hepatol. 2023;79(5):1185\u2013200.","journal-title":"J Hepatol"},{"key":"764_CR31","doi-asserted-by":"crossref","unstructured":"Wu K, Li L, Liu Y, Wang K, Zheng J, Liang H, et al. PCK1 deficiency promotes MASH-HCC progression by 12-HETE-induced CD8+ T cell dysfunction. Gut. 2025.","DOI":"10.1136\/gutjnl-2024-334562"},{"key":"764_CR32","doi-asserted-by":"publisher","first-page":"115131","DOI":"10.1016\/j.biopha.2023.115131","volume":"165","author":"X Zhong","year":"2023","unstructured":"Zhong X, Lv M, Ma M, Huang Q, Hu R, Li J, et al. State of CD8+ T cells in progression from nonalcoholic steatohepatitis to hepatocellular carcinoma: From pathogenesis to immunotherapy. Biomed Pharmacother. 2023;165:115131.","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"764_CR33","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1158\/2326-6066.CIR-24-1088","volume":"13","author":"Z Wang","year":"2025","unstructured":"Wang Z, Zhang Y, Li X, Xia N, Han S, Pu L, et al. Targeting Myeloid Trem2 Reprograms the Immunosuppressive Niche and Potentiates Checkpoint Immunotherapy in NASH-Driven Hepatocarcinogenesis. Cancer Immunol Res. 2025;13(10):1516\u201332.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"764_CR34","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.1038\/s41467-018-07402-8","volume":"9","author":"H Sun","year":"2018","unstructured":"Sun H, Yang W, Tian Y, Zeng X, Zhou J, Mok MTS, et al. An inflammatory-CCRK circuitry drives mTORC1-dependent metabolic and immunosuppressive reprogramming in obesity-associated hepatocellular carcinoma. Nat Commun. 2018;9(1):5214.","journal-title":"Nat Commun"},{"issue":"47","key":"764_CR35","doi-asserted-by":"publisher","first-page":"5055","DOI":"10.3748\/wjg.v30.i47.5055","volume":"30","author":"LL Wang","year":"2024","unstructured":"Wang LL, Lu YM, Wang YH, Wang YF, Fang RF, Sai WL, et al. Carnitine palmitoyltransferase-II inactivity promotes malignant progression of metabolic dysfunction-associated fatty liver disease via liver cancer stem cell activation. World J Gastroenterol. 2024;30(47):5055\u201369.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"764_CR36","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/s41419-018-0687-6","volume":"9","author":"ZJ Brown","year":"2018","unstructured":"Brown ZJ, Fu Q, Ma C, Kruhlak M, Zhang H, Luo J, et al. Carnitine palmitoyltransferase gene upregulation by linoleic acid induces CD4(+) T cell apoptosis promoting HCC development. Cell Death Dis. 2018;9(6):620.","journal-title":"Cell Death Dis"},{"issue":"4","key":"764_CR37","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1002\/hep.29914","volume":"68","author":"DJ van der Windt","year":"2018","unstructured":"van der Windt DJ, Sud V, Zhang H, Varley PR, Goswami J, Yazdani HO, et al. Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in nonalcoholic steatohepatitis. Hepatology. 2018;68(4):1347\u201360.","journal-title":"Hepatology"},{"key":"764_CR38","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.semcancer.2023.04.010","volume":"93","author":"SA Polyzos","year":"2023","unstructured":"Polyzos SA, Chrysavgis L, Vachliotis ID, Chartampilas E, Cholongitas E. Nonalcoholic fatty liver disease and hepatocellular carcinoma:Insights in epidemiology, pathogenesis, imaging, prevention and therapy. Semin Cancer Biol. 2023;93:20\u201335.","journal-title":"Semin Cancer Biol"},{"issue":"6145","key":"764_CR39","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1126\/science.1241165","volume":"341","author":"PM Smith","year":"2013","unstructured":"Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly YM, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341(6145):569\u201373.","journal-title":"Science"},{"key":"764_CR40","doi-asserted-by":"publisher","first-page":"108273","DOI":"10.1016\/j.micpath.2025.108273","volume":"211","author":"G Singh","year":"2026","unstructured":"Singh G, Ansari S, Yadav S, Aran KR. Gut microbiota\u2019s role in NAFLD- and HBV\/HCV-related hepatocellular carcinoma: Mechanisms and therapeutic implications. Microb Pathog. 2026;211:108273.","journal-title":"Microb Pathog"},{"issue":"1","key":"764_CR41","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41467-020-20422-7","volume":"12","author":"J Behary","year":"2021","unstructured":"Behary J, Amorim N, Jiang XT, Raposo A, Gong L, McGovern E, et al. Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma. Nat Commun. 2021;12(1):187.","journal-title":"Nat Commun"},{"issue":"1","key":"764_CR42","doi-asserted-by":"publisher","first-page":"2221485","DOI":"10.1080\/19490976.2023.2221485","volume":"15","author":"Y Han","year":"2023","unstructured":"Han Y, Ling Q, Wu L, Wang X, Wang Z, Chen J, et al. Akkermansia muciniphila inhibits nonalcoholic steatohepatitis by orchestrating TLR2-activated \u03b3\u03b4T17 cell and macrophage polarization. Gut Microbes. 2023;15(1):2221485.","journal-title":"Gut Microbes"},{"issue":"1","key":"764_CR43","doi-asserted-by":"publisher","first-page":"101900","DOI":"10.1016\/j.xcrm.2024.101900","volume":"6","author":"XQ Wu","year":"2025","unstructured":"Wu XQ, Ying F, Chung KPS, Leung CON, Leung RWH, So KKH, et al. Intestinal Akkermansia muciniphila complements the efficacy of PD1 therapy in MAFLD-related hepatocellular carcinoma. Cell Rep Med. 2025;6(1):101900.","journal-title":"Cell Rep Med"},{"issue":"10","key":"764_CR44","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1136\/gutjnl-2021-326259","volume":"71","author":"J Leslie","year":"2022","unstructured":"Leslie J, Mackey JBG, Jamieson T, Ramon-Gil E, Drake TM, Fercoq F, et al. CXCR2 inhibition enables NASH-HCC immunotherapy. Gut. 2022;71(10):2093\u2013106.","journal-title":"Gut"},{"issue":"3","key":"764_CR45","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.jhep.2022.03.010","volume":"77","author":"S Wabitsch","year":"2022","unstructured":"Wabitsch S, McCallen JD, Kamenyeva O, Ruf B, McVey JC, Kabat J, et al. Metformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD. J Hepatol. 2022;77(3):748\u201360.","journal-title":"J Hepatol"},{"issue":"8","key":"764_CR46","doi-asserted-by":"publisher","first-page":"101144","DOI":"10.1016\/j.xcrm.2023.101144","volume":"4","author":"Y Pan","year":"2023","unstructured":"Pan Y, Chen H, Zhang X, Liu W, Ding Y, Huang D, et al. METTL3 drives NAFLD-related hepatocellular carcinoma and is a therapeutic target for boosting immunotherapy. Cell Rep Med. 2023;4(8):101144.","journal-title":"Cell Rep Med"},{"issue":"8","key":"764_CR47","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41575-023-00760-9","volume":"20","author":"YC Hsu","year":"2023","unstructured":"Hsu YC, Huang DQ, Nguyen MH. Global burden of hepatitis B virus: current status, missed opportunities and a call for action. Nat Rev Gastroenterol Hepatol. 2023;20(8):524\u201337.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"764_CR48","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S2468-1253(21)00472-6","volume":"7","author":"Global change in","year":"2022","unstructured":"Global change in. hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol. 2022;7(5):396\u2013415.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"764_CR49","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","volume":"135","author":"C Xia","year":"2022","unstructured":"Xia C, Dong X, Li H, Cao M, Sun D, He S, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl). 2022;135(5):584\u201390.","journal-title":"Chin Med J (Engl)"},{"issue":"9","key":"764_CR50","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1038\/s41590-024-01928-4","volume":"25","author":"K Heim","year":"2024","unstructured":"Heim K, Sagar, Sogukpinar \u00d6, Llewellyn-Lacey S, Price DA, Emmerich F, et al. Attenuated effector T cells are linked to control of chronic HBV infection. Nat Immunol. 2024;25(9):1650\u201362.","journal-title":"Nat Immunol"},{"issue":"3","key":"764_CR51","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.ccr.2012.07.023","volume":"22","author":"P Yang","year":"2012","unstructured":"Yang P, Li QJ, Feng Y, Zhang Y, Markowitz GJ, Ning S, et al. TGF-\u03b2-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell. 2012;22(3):291\u2013303.","journal-title":"Cancer Cell"},{"issue":"1","key":"764_CR52","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41392-024-01764-w","volume":"9","author":"Z Deng","year":"2024","unstructured":"Deng Z, Fan T, Xiao C, Tian H, Zheng Y, Li C, et al. TGF-\u03b2 signaling in health, disease, and therapeutics. Signal Transduct Target Ther. 2024;9(1):61.","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"764_CR53","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1136\/gutjnl-2022-327202","volume":"72","author":"M Rossi","year":"2023","unstructured":"Rossi M, Vecchi A, Tiezzi C, Barili V, Fisicaro P, Penna A, et al. Phenotypic CD8 T cell profiling in chronic hepatitis B to predict HBV-specific CD8 T cell susceptibility to functional restoration in vitro. Gut. 2023;72(11):2123\u201337.","journal-title":"Gut"},{"issue":"10","key":"764_CR54","doi-asserted-by":"publisher","first-page":"e1012615","DOI":"10.1371\/journal.ppat.1012615","volume":"20","author":"J Lopez-Scarim","year":"2024","unstructured":"Lopez-Scarim J, Mendoza D, Nambiar SM, Billerbeck E. CD4\u2009+\u2009T cell help during early acute hepacivirus infection is critical for viral clearance and the generation of a liver-homing CD103\u2009+\u2009CD49a+ effector CD8\u2009+\u2009T cell subset. PLoS Pathog. 2024;20(10):e1012615.","journal-title":"PLoS Pathog"},{"issue":"1","key":"764_CR55","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s10238-025-01928-0","volume":"25","author":"T Ma","year":"2025","unstructured":"Ma T, Zhao F, Yao L, Mao C, Tian Y, Ma Y, et al. The interplay between hepatitis B virus and antitumor drugs in the treatment of hepatocellular carcinoma. Clin Exp Med. 2025;25(1):334.","journal-title":"Clin Exp Med"},{"issue":"1","key":"764_CR56","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.jhep.2016.02.016","volume":"64","author":"D Durantel","year":"2016","unstructured":"Durantel D, Zoulim F. New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus. J Hepatol. 2016;64(1):S117\u201331.","journal-title":"J Hepatol"},{"issue":"6","key":"764_CR57","doi-asserted-by":"publisher","first-page":"592","DOI":"10.3390\/v12060592","volume":"12","author":"L Lauterbach-Rivi\u00e8re","year":"2020","unstructured":"Lauterbach-Rivi\u00e8re L, Bergez M, M\u00f6nch S, Qu B, Riess M, Vondran FWR, et al. Hepatitis B Virus DNA is a Substrate for the cGAS\/STING Pathway but is not Sensed in Infected Hepatocytes. Viruses. 2020;12(6):592.","journal-title":"Viruses"},{"key":"764_CR58","doi-asserted-by":"crossref","unstructured":"Verrier ER, Yim SA, Heydmann L, El Saghire H, Bach C, Turon-Lagot V, et al. Hepatitis B virus evasion from cyclic guanosine monophosphate\u2013adenosine monophosphate synthase sensing in human hepatocytes. Hepatology. 2018;68(5).","DOI":"10.1002\/hep.30054"},{"key":"764_CR59","doi-asserted-by":"publisher","first-page":"110199","DOI":"10.1016\/j.virol.2024.110199","volume":"599","author":"A Kar","year":"2024","unstructured":"Kar A, Mukherjee S, Mukherjee S, Biswas A, Ubiquitin. A double-edged sword in hepatitis B virus-induced hepatocellular carcinoma. Virology. 2024;599:110199.","journal-title":"Virology"},{"issue":"1","key":"764_CR60","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41467-020-20316-8","volume":"12","author":"L Zhou","year":"2021","unstructured":"Zhou L, He R, Fang P, Li M, Yu H, Wang Q, et al. Hepatitis B virus rigs the cellular metabolome to avoid innate immune recognition. Nat Commun. 2021;12(1):98.","journal-title":"Nat Commun"},{"issue":"1","key":"764_CR61","doi-asserted-by":"publisher","first-page":"2607229","DOI":"10.1080\/07853890.2025.2607229","volume":"58","author":"R Song","year":"2026","unstructured":"Song R, Li M, Tang S, Zhang G. Immunotherapy for virus-related hepatocellular carcinoma: recent progress and future directions. Ann Med. 2026;58(1):2607229.","journal-title":"Ann Med"},{"issue":"2","key":"764_CR62","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1053\/j.gastro.2009.09.052","volume":"138","author":"P Fisicaro","year":"2010","unstructured":"Fisicaro P, Valdatta C, Massari M, Loggi E, Biasini E, Sacchelli L, et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology. 2010;138(2):682\u201393. 93.e.","journal-title":"Gastroenterology"},{"issue":"5","key":"764_CR63","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","volume":"71","author":"E Gane","year":"2019","unstructured":"Gane E, Verdon DJ, Brooks AE, Gaggar A, Nguyen AH, Subramanian GM, et al. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study. J Hepatol. 2019;71(5):900\u20137.","journal-title":"J Hepatol"},{"issue":"4","key":"764_CR64","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862\u201373.","journal-title":"J Hepatol"},{"issue":"4","key":"764_CR65","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1158\/0008-5472.CAN-22-2273","volume":"83","author":"X Cheng","year":"2023","unstructured":"Cheng X, Tan X, Wang W, Zhang Z, Zhu R, Wu M, et al. Long-Chain Acylcarnitines Induce Senescence of Invariant Natural Killer T Cells in Hepatocellular Carcinoma. Cancer Res. 2023;83(4):582\u201394.","journal-title":"Cancer Res"},{"issue":"48","key":"764_CR66","doi-asserted-by":"publisher","first-page":"4747","DOI":"10.1038\/s41388-025-03625-4","volume":"44","author":"W Chen","year":"2025","unstructured":"Chen W, Lin C, Wang L, Yu Z, Xu Y, Zhang M, et al. Hepatitis B virus X protein promotes the progression and immune escape of hepatocellular carcinoma by activating KLF16-C12orf49-PD-L1 axis. Oncogene. 2025;44(48):4747\u201362.","journal-title":"Oncogene"},{"key":"764_CR67","doi-asserted-by":"publisher","first-page":"118515","DOI":"10.1016\/j.biopha.2025.118515","volume":"191","author":"L Qi","year":"2025","unstructured":"Qi L, Hu B, Cao C, Peng T, Xu M, Liu S, et al. Viral oncogenesis and immune remodeling: Decoding the therapeutic potential of immune checkpoint inhibitors in virus-associated cancers. Biomed Pharmacother. 2025;191:118515.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"764_CR68","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jhep.2021.08.029","volume":"76","author":"Y Gao","year":"2022","unstructured":"Gao Y, You M, Fu J, Tian M, Zhong X, Du C, et al. Intratumoral stem-like CCR4\u2009+\u2009regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B. J Hepatol. 2022;76(1):148\u201359.","journal-title":"J Hepatol"},{"issue":"4","key":"764_CR69","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1053\/j.gastro.2016.12.021","volume":"152","author":"S Ravi","year":"2017","unstructured":"Ravi S, Axley P, Jones D, Kodali S, Simpson H, McGuire BM, et al. Unusually High Rates of Hepatocellular Carcinoma After Treatment With Direct-Acting Antiviral Therapy for Hepatitis C Related Cirrhosis. Gastroenterology. 2017;152(4):911\u20132.","journal-title":"Gastroenterology"},{"issue":"22","key":"764_CR70","doi-asserted-by":"publisher","first-page":"16100","DOI":"10.3390\/ijms242216100","volume":"24","author":"S Barik","year":"2023","unstructured":"Barik S. Suppression of Innate Immunity by the Hepatitis C Virus (HCV): Revisiting the Specificity of Host\u2013Virus Interactive Pathways. Int J Mol Sci. 2023;24(22):16100.","journal-title":"Int J Mol Sci"},{"key":"764_CR71","doi-asserted-by":"crossref","unstructured":"Ouaguia L, Moral\u00e8s O, Aoudjehane L, Wychowski C, Kumar A, Dubuisson J, et al. Hepatitis C virus improves human Tregs suppressive function and promotes their recruitment to the liver. Cells. 2019;8(10).","DOI":"10.3390\/cells8101296"},{"issue":"1","key":"764_CR72","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3748\/wjg.v25.i1.42","volume":"25","author":"S Mahmoudvand","year":"2019","unstructured":"Mahmoudvand S, Shokri S, Taherkhani R, Farshadpour F. Hepatitis C virus core protein modulates several signaling pathways involved in hepatocellular carcinoma. World J Gastroenterol. 2019;25(1):42\u201358.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"764_CR73","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1053\/j.gastro.2021.06.008","volume":"161","author":"PK Haber","year":"2021","unstructured":"Haber PK, Puigveh\u00ed M, Castet F, Lourdusamy V, Montal R, Tabrizian P, et al. Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002\u20132020). Gastroenterology. 2021;161(3):879\u201398.","journal-title":"Gastroenterology"},{"issue":"8","key":"764_CR74","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.3390\/cells10081917","volume":"10","author":"S Mukherjee","year":"2021","unstructured":"Mukherjee S, Kar A, Khatun N, Datta P, Biswas A, Barik S. Familiarity Breeds Strategy: In Silico Untangling of the Molecular Complexity on Course of Autoimmune Liver Disease-to-Hepatocellular Carcinoma Transition Predicts Novel Transcriptional Signatures. Cells. 2021;10(8):1917.","journal-title":"Cells"},{"issue":"5","key":"764_CR75","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1084\/jem.20160935","volume":"214","author":"L Bakiri","year":"2017","unstructured":"Bakiri L, Hamacher R, Gra\u00f1a O, Gu\u00edo-Carri\u00f3n A, Campos-Olivas R, Martinez L, et al. Liver carcinogenesis by FOS-dependent inflammation and cholesterol dysregulation. J Exp Med. 2017;214(5):1387\u2013409.","journal-title":"J Exp Med"},{"key":"764_CR76","doi-asserted-by":"publisher","first-page":"1324140","DOI":"10.3389\/fphar.2024.1324140","volume":"15","author":"J Wang","year":"2024","unstructured":"Wang J, Liu C, Hu R, Wu L, Li C. Statin therapy: a potential adjuvant to immunotherapies in hepatocellular carcinoma. Front Pharmacol. 2024;15:1324140.","journal-title":"Front Pharmacol"},{"issue":"1","key":"764_CR77","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12951-021-01205-8","volume":"20","author":"Z Yu","year":"2022","unstructured":"Yu Z, Guo J, Liu Y, Wang M, Liu Z, Gao Y, et al. Nano delivery of simvastatin targets liver sinusoidal endothelial cells to remodel tumor microenvironment for hepatocellular carcinoma. J Nanobiotechnol. 2022;20(1):9.","journal-title":"J Nanobiotechnol"},{"issue":"4","key":"764_CR78","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/liv.15833","volume":"44","author":"FD Copil","year":"2024","unstructured":"Copil FD, Campani C, Lequoy M, Sultanik P, Blaise L, Wagner M, et al. No correlation between MASLD and poor outcome of Atezolizumab-Bevacizumab therapy in patients with advanced HCC. Liver Int. 2024;44(4):931\u201343.","journal-title":"Liver Int"},{"issue":"1","key":"764_CR79","doi-asserted-by":"publisher","first-page":"41844","DOI":"10.1038\/s41598-025-25752-4","volume":"15","author":"A Dalbeni","year":"2025","unstructured":"Dalbeni A, Cattazzo F, Vicardi M, Franceschini E, Campani C, Cabibbo G, et al. Statins and clinical outcomes in patients with advanced hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab. Sci Rep. 2025;15(1):41844.","journal-title":"Sci Rep"},{"key":"764_CR80","doi-asserted-by":"publisher","first-page":"116094","DOI":"10.1016\/j.ejca.2025.116094","volume":"231","author":"W Sohn","year":"2025","unstructured":"Sohn W, Hong S, Han K, Park CY. Reduced risk of hepatocellular carcinoma in the use of fibrate as an add-on to statin: A retrospective population-based cohort study. Eur J Cancer. 2025;231:116094.","journal-title":"Eur J Cancer"},{"issue":"Pt 3","key":"764_CR81","doi-asserted-by":"publisher","first-page":"117367","DOI":"10.1016\/j.bcp.2025.117367","volume":"242","author":"J Wang","year":"2025","unstructured":"Wang J, Chen L, Jiang L, Wang Y, Xue W, Cai X, et al. Dual activation of PPAR\u03b1\/\u03b3 by bezafibrate triggers PINK1\/Parkin-Mediated mitophagy to enhance lenvatinib sensitivity in hepatocellular carcinoma. Biochem Pharmacol. 2025;242(Pt 3):117367.","journal-title":"Biochem Pharmacol"},{"key":"764_CR82","doi-asserted-by":"crossref","unstructured":"Liang X, Li Y, Cai J, Luo L, Yang P, Chen Y, et al. Fibrates inhibit PLTP-induced M2 macrophage infiltration and increase the sensitivity of hepatocellular carcinoma to ICIs. Adv Sci (Weinh). 2025:e13257.","DOI":"10.1002\/advs.202513257"},{"issue":"10","key":"764_CR83","doi-asserted-by":"publisher","first-page":"4677","DOI":"10.1002\/tox.24295","volume":"39","author":"X Huang","year":"2024","unstructured":"Huang X, You D, An T, Zhao X, Jiang T, Huang Z. Glycyrrhizic acid attenuates the malignant biological properties of nonalcoholic fatty liver disease-related hepatocellular carcinoma. Environ Toxicol. 2024;39(10):4677\u201388.","journal-title":"Environ Toxicol"},{"issue":"6","key":"764_CR84","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1080\/00365521.2024.2315317","volume":"59","author":"Y Hu","year":"2024","unstructured":"Hu Y, Luo Z, Cai S, Xie Q, Zheng S. Glycyrrhizic acid attenuates sorafenib resistance by inducing ferroptosis via targeting mTOR signaling in hepatocellular carcinoma. Scand J Gastroenterol. 2024;59(6):730\u20136.","journal-title":"Scand J Gastroenterol"},{"key":"764_CR85","doi-asserted-by":"publisher","first-page":"109770","DOI":"10.1016\/j.clim.2023.109770","volume":"256","author":"C Zhou","year":"2023","unstructured":"Zhou C, Sun BY, Zhou PY, Yang ZF, Wang ZT, Liu G, et al. MAIT cells confer resistance to Lenvatinib plus anti-PD1 antibodies in hepatocellular carcinoma through TNF-TNFRSF1B pathway. Clin Immunol. 2023;256:109770.","journal-title":"Clin Immunol"},{"issue":"1","key":"764_CR86","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s40364-025-00844-5","volume":"13","author":"L An","year":"2025","unstructured":"An L, Li Z. Molecular network of metabolic reprogramming and precision diagnosis and treatment of hepatocellular carcinoma. Biomark Res. 2025;13(1):124.","journal-title":"Biomark Res"},{"key":"764_CR87","doi-asserted-by":"crossref","unstructured":"Cao M, Gao Y, Zhan M, Qiu N, Piao Y, Zhou Z, et al. Glycyrrhizin acid and glycyrrhetinic acid modified polyethyleneimine for targeted DNA delivery to hepatocellular carcinoma. Int J Mol Sci. 2019;20(20).","DOI":"10.3390\/ijms20205074"},{"issue":"12","key":"764_CR88","doi-asserted-by":"publisher","first-page":"e83699","DOI":"10.1371\/journal.pone.0083699","volume":"8","author":"S Zhang","year":"2013","unstructured":"Zhang S, Yang Y, Liang Z, Duan W, Yang J, Yan J, et al. Silybin-mediated inhibition of Notch signaling exerts antitumor activity in human hepatocellular carcinoma cells. PLoS ONE. 2013;8(12):e83699.","journal-title":"PLoS ONE"},{"key":"764_CR89","doi-asserted-by":"publisher","first-page":"112409","DOI":"10.1016\/j.biopha.2021.112409","volume":"145","author":"NYS Yassin","year":"2022","unstructured":"Yassin NYS, AbouZid SF, El-Kalaawy AM, Ali TM, Almehmadi MM, Ahmed OM. Silybum marianum total extract, silymarin and silibinin abate hepatocarcinogenesis and hepatocellular carcinoma growth via modulation of the HGF\/c-Met, Wnt\/\u03b2-catenin, and PI3K\/Akt\/mTOR signaling pathways. Biomed Pharmacother. 2022;145:112409.","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"764_CR90","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1002\/ptr.7716","volume":"37","author":"MJ MasodKhooy","year":"2023","unstructured":"MasodKhooy MJ, Farasat M, Salehi Salmi M, Mirzaei H. Combinatorial treatment with Silybum marianum essential oil enhances the therapeutic efficacy of a 5-fluorouracil base therapy for hepatocellular carcinoma. Phytother Res. 2023;37(5):1968\u201385.","journal-title":"Phytother Res"},{"issue":"1","key":"764_CR91","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.canlet.2012.07.028","volume":"326","author":"E Brandon-Warner","year":"2012","unstructured":"Brandon-Warner E, Eheim AL, Foureau DM, Walling TL, Schrum LW, McKillop IH. Silibinin (Milk Thistle) potentiates ethanol-dependent hepatocellular carcinoma progression in male mice. Cancer Lett. 2012;326(1):88\u201395.","journal-title":"Cancer Lett"},{"issue":"10","key":"764_CR92","doi-asserted-by":"publisher","first-page":"e74130","DOI":"10.1371\/journal.pone.0074130","volume":"8","author":"H Lin","year":"2013","unstructured":"Lin H, Liu XB, Yu JJ, Hua F, Hu ZW. Antioxidant N-acetylcysteine attenuates hepatocarcinogenesis by inhibiting ROS\/ER stress in TLR2 deficient mouse. PLoS ONE. 2013;8(10):e74130.","journal-title":"PLoS ONE"},{"issue":"1","key":"764_CR93","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s13578-021-00731-0","volume":"11","author":"VX Zhang","year":"2021","unstructured":"Zhang VX, Sze KM, Chan LK, Ho DW, Tsui YM, Chiu YT, et al. Antioxidant supplements promote tumor formation and growth and confer drug resistance in hepatocellular carcinoma by reducing intracellular ROS and induction of TMBIM1. Cell Biosci. 2021;11(1):217.","journal-title":"Cell Biosci"},{"issue":"1","key":"764_CR94","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1476-5926-11-4","volume":"11","author":"NA Kretzmann","year":"2012","unstructured":"Kretzmann NA, Chiela E, Matte U, Marroni N, Marroni CA. N-acetylcysteine improves antitumoural response of Interferon alpha by NF-kB downregulation in liver cancer cells. Comp Hepatol. 2012;11(1):4.","journal-title":"Comp Hepatol"},{"key":"764_CR95","doi-asserted-by":"publisher","first-page":"139927","DOI":"10.1016\/j.jcis.2026.139927","volume":"709","author":"Z He","year":"2026","unstructured":"He Z, Zhang L, Gao X, Zhong J, Zhang Y, Gao F. Glutathione- responsive Phototheranostic platform for imaging-guided enhanced oxidation photoimmunotherapy-ferroptosis synergistic hepatocellular carcinoma therapy. J Colloid Interface Sci. 2026;709:139927.","journal-title":"J Colloid Interface Sci"},{"issue":"6730","key":"764_CR96","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1126\/science.adl4100","volume":"387","author":"SK Varanasi","year":"2025","unstructured":"Varanasi SK, Chen D, Liu Y, Johnson MA, Miller CM, Ganguly S, et al. Bile acid synthesis impedes tumor-specific T cell responses during liver cancer. Science. 2025;387(6730):192\u2013201.","journal-title":"Science"},{"key":"764_CR97","doi-asserted-by":"publisher","first-page":"107396","DOI":"10.1016\/j.pharmthera.2019.107396","volume":"203","author":"JF Goossens","year":"2019","unstructured":"Goossens JF, Bailly C. Ursodeoxycholic acid and cancer: From chemoprevention to chemotherapy. Pharmacol Ther. 2019;203:107396.","journal-title":"Pharmacol Ther"},{"key":"764_CR98","doi-asserted-by":"crossref","unstructured":"Hsu YF, Kung FL, Huang TE, Deng YN, Guh JH, Marchetti P, et al. Anticancer activity and molecular mechanisms of an ursodeoxycholic acid methyl ester\u2013dihydroartemisinin hybrid via a triazole linkage in hepatocellular carcinoma cells. Molecules. 2023;28(5).","DOI":"10.3390\/molecules28052358"},{"key":"764_CR99","doi-asserted-by":"crossref","unstructured":"Kariyama K, Nouso K, Hiraoka A, Tada F, Ohama H, Toyoda H, et al. Evolution of hepatocellular carcinoma treatment outcomes over two decades in Japan: improvements in early-stage viral disease. Hepatol Res. 2025.","DOI":"10.1111\/hepr.70070"},{"key":"764_CR100","doi-asserted-by":"crossref","unstructured":"Mert K, Tatar B, Nadir Y, Senger SS. Monitoring the effect of antiviral treatment on the development of cirrhosis and hepatocellular carcinoma in chronic hepatitis B patients. Rev Assoc Med Bras (1992). 2024;70(12):e20240803.","DOI":"10.1590\/1806-9282.20240803"},{"issue":"1","key":"764_CR101","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1038\/s41467-025-57367-8","volume":"16","author":"Y Gao","year":"2025","unstructured":"Gao Y, Zhang Z, Huang X, You M, Du C, Li N, et al. HBV-associated hepatocellular carcinomas inhibit antitumor CD8+ T cell via the long noncoding RNA HDAC2-AS2. Nat Commun. 2025;16(1):2055.","journal-title":"Nat Commun"},{"issue":"2","key":"764_CR102","doi-asserted-by":"publisher","first-page":"108195","DOI":"10.1016\/j.jbc.2025.108195","volume":"301","author":"Y Sheng","year":"2025","unstructured":"Sheng Y, Lin Y, Qiang Z, Shen X, He Y, Li L, et al. Protein kinase a suppresses antiproliferative effect of interferon-\u03b1 in hepatocellular carcinoma by activation of protein tyrosine phosphatase SHP2. J Biol Chem. 2025;301(2):108195.","journal-title":"J Biol Chem"},{"issue":"1","key":"764_CR103","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/hep.510310111","volume":"31","author":"JM Llovet","year":"2000","unstructured":"Llovet JM, Sala M, Castells L, Suarez Y, Vilana R, Bianchi L, et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology. 2000;31(1):54\u20138.","journal-title":"Hepatology"},{"issue":"7","key":"764_CR104","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1158\/2159-8290.CD-21-1022","volume":"12","author":"B Hu","year":"2022","unstructured":"Hu B, Yu M, Ma X, Sun J, Liu C, Wang C, et al. IFN\u03b1 Potentiates Anti-PD-1 Efficacy by Remodeling Glucose Metabolism in the Hepatocellular Carcinoma Microenvironment. Cancer Discov. 2022;12(7):1718\u201341.","journal-title":"Cancer Discov"},{"issue":"2","key":"764_CR105","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/jvh.13778","volume":"30","author":"W Abdelhamed","year":"2023","unstructured":"Abdelhamed W, El-Kassas M. Hepatocellular carcinoma and hepatitis C virus treatments: The bold and the beautiful. J Viral Hepat. 2023;30(2):148\u201359.","journal-title":"J Viral Hepat"},{"issue":"9","key":"764_CR106","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1111\/jgh.15915","volume":"37","author":"H Liu","year":"2022","unstructured":"Liu H, Yang XL, Dong ZR, Chen ZQ, Hong JG, Wang DX, et al. Clinical benefits of direct-acting antivirals therapy in hepatitis C virus patients with hepatocellular carcinoma: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2022;37(9):1654\u201365.","journal-title":"J Gastroenterol Hepatol"},{"key":"764_CR107","doi-asserted-by":"crossref","unstructured":"Sung PS, Shin EC. Immunological mechanisms for hepatocellular carcinoma risk after direct-acting antiviral treatment of hepatitis C virus infection. J Clin Med. 2021;10(2).","DOI":"10.3390\/jcm10020221"},{"key":"764_CR108","doi-asserted-by":"crossref","unstructured":"Miranda-Roblero HO, Saavedra-Salazar LF, Galicia-Moreno M, Arceo-Orozco S, Caloca-Camarena F, Sandoval-Rodriguez A, et al. Pirfenidone reverts global DNA hypomethylation, promoting DNMT1\/UHRF\/PCNA coupling complex in experimental hepatocarcinoma. Cells. 2024;13(12).","DOI":"10.3390\/cells13121013"},{"issue":"3","key":"764_CR109","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/hep4.1474","volume":"4","author":"A Sandoval-Rodriguez","year":"2020","unstructured":"Sandoval-Rodriguez A, Monroy-Ramirez HC, Meza-Rios A, Garcia-Ba\u00f1uelos J, Vera-Cruz J, Guti\u00e9rrez-Cuevas J, et al. Pirfenidone Is an Agonistic Ligand for PPAR\u03b1 and Improves NASH by Activation of SIRT1\/LKB1\/pAMPK. Hepatol Commun. 2020;4(3):434\u201349.","journal-title":"Hepatol Commun"},{"issue":"7","key":"764_CR110","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/intbio\/zyaa014","volume":"12","author":"H Aboulkheyr Es","year":"2020","unstructured":"Aboulkheyr Es H, Zhand S, Thiery JP, Warkiani ME. Pirfenidone reduces immune-suppressive capacity of cancer-associated fibroblasts through targeting CCL17 and TNF-beta. Integr Biol (Camb). 2020;12(7):188\u201397.","journal-title":"Integr Biol (Camb)"},{"issue":"1","key":"764_CR111","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ejphar.2011.12.025","volume":"678","author":"J Navarro-Partida","year":"2012","unstructured":"Navarro-Partida J, Martinez-Rizo AB, Gonzalez-Cuevas J, Arrevillaga-Boni G, Ortiz-Navarrete V, Armendariz-Borunda J. Pirfenidone restricts Th2 differentiation in vitro and limits Th2 response in experimental liver fibrosis. Eur J Pharmacol. 2012;678(1):71\u20137.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"764_CR112","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jhep.2014.03.017","volume":"61","author":"WT Tai","year":"2014","unstructured":"Tai WT, Shiau CW, Li YS, Chang CW, Huang JW, Hsueh TT, et al. Nintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity. J Hepatol. 2014;61(1):89\u201397.","journal-title":"J Hepatol"},{"key":"764_CR113","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.intimp.2019.03.061","volume":"72","author":"N Bellamri","year":"2019","unstructured":"Bellamri N, Morzadec C, Joannes A, Lecureur V, Wollin L, Jouneau S, et al. Alteration of human macrophage phenotypes by the anti-fibrotic drug nintedanib. Int Immunopharmacol. 2019;72:112\u201323.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"764_CR114","doi-asserted-by":"publisher","first-page":"100872","DOI":"10.1016\/j.tranon.2020.100872","volume":"14","author":"X Lu","year":"2021","unstructured":"Lu X, Xu C, Dong J, Zuo S, Zhang H, Jiang C, et al. Liraglutide activates nature killer cell-mediated antitumor responses by inhibiting IL-6\/STAT3 signaling in hepatocellular carcinoma. Transl Oncol. 2021;14(1):100872.","journal-title":"Transl Oncol"},{"issue":"1","key":"764_CR115","doi-asserted-by":"publisher","first-page":"12502","DOI":"10.1038\/s41598-017-12629-4","volume":"7","author":"YM Attia","year":"2017","unstructured":"Attia YM, Tawfiq RA, Ali AA, Elmazar MM. The FXR Agonist, Obeticholic Acid, Suppresses HCC Proliferation & Metastasis: Role of IL-6\/STAT3 Signalling Pathway. Sci Rep. 2017;7(1):12502.","journal-title":"Sci Rep"},{"issue":"11","key":"764_CR116","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1016\/j.apsb.2020.09.004","volume":"10","author":"G Ji","year":"2020","unstructured":"Ji G, Ma L, Yao H, Ma S, Si X, Wang Y, et al. Precise delivery of obeticholic acid via nanoapproach for triggering natural killer T cell-mediated liver cancer immunotherapy. Acta Pharm Sin B. 2020;10(11):2171\u201382.","journal-title":"Acta Pharm Sin B"},{"key":"764_CR117","doi-asserted-by":"publisher","first-page":"711448","DOI":"10.3389\/fonc.2021.711448","volume":"11","author":"Y Gong","year":"2021","unstructured":"Gong Y, Li K, Qin Y, Zeng K, Liu J, Huang S, et al. Norcholic Acid Promotes Tumor Progression and Immune Escape by Regulating Farnesoid X Receptor in Hepatocellular Carcinoma. Front Oncol. 2021;11:711448.","journal-title":"Front Oncol"},{"key":"764_CR118","doi-asserted-by":"crossref","unstructured":"Ma Z, Jia W, Zhou X, Liu J, Li Q, Chang R, et al. In vivo CRISPR screens identify CBX4 as an epigenetic regulator for cancer immunotherapy. J Clin Invest. 2026.","DOI":"10.1172\/JCI200564"},{"key":"764_CR119","doi-asserted-by":"publisher","first-page":"218449","DOI":"10.1016\/j.canlet.2026.218449","volume":"647","author":"J Liu","year":"2026","unstructured":"Liu J, Liu X, Li Z, Yu X, Qian J, Zhang Z, et al. Targeting MSR1(+) tumor-associated macrophages enhances the therapeutic efficacy of anti-PD-L1 in hepatocellular carcinoma by suppressing NF-\u03baB pathway activation. Cancer Lett. 2026;647:218449.","journal-title":"Cancer Lett"},{"key":"764_CR120","doi-asserted-by":"publisher","first-page":"1765930","DOI":"10.3389\/fimmu.2026.1765930","volume":"17","author":"M Hu","year":"2026","unstructured":"Hu M, Zhang N, Wang YQ, Wang XM, Shi Y, Yao M, et al. GNPAT promotes immunosuppression in hepatocellular carcinoma by activating the plasmalogen-PPAR\u03b3 pathway to drive M2 macrophage polarization. Front Immunol. 2026;17:1765930.","journal-title":"Front Immunol"},{"key":"764_CR121","doi-asserted-by":"crossref","unstructured":"Chen S, Wang B, Zhang Y, Quan B, Shao Y, Zhu G, et al. HKDC1-mediated polyamine rewiring drives lenvatinib resistance and immune escape in hepatocellular carcinoma. Clin Mol Hepatol. 2026.","DOI":"10.3350\/cmh.2025.1269"},{"issue":"38","key":"764_CR122","doi-asserted-by":"publisher","first-page":"e2510576122","DOI":"10.1073\/pnas.2510576122","volume":"122","author":"Y Yuan","year":"2025","unstructured":"Yuan Y, Niu Y, Huang Z, Shi Y, Lin Z, Zuo D, et al. USP14-mediated metabolic competition impairs CD8\u2009+\u2009T cell immunosurveillance in hepatocellular carcinoma. Proc Natl Acad Sci U S A. 2025;122(38):e2510576122.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"764_CR123","doi-asserted-by":"publisher","first-page":"101280","DOI":"10.1016\/j.neo.2026.101280","volume":"73","author":"J Zhang","year":"2026","unstructured":"Zhang J, Gu Y, Zhao F, Chen Y, Xia Y, Gao D, et al. Targeting the ANXA2-CD63-exosomal PD-L1 axis in hepatocellular carcinoma: A novel mechanism of immune evasion and its implications for precision immunotherapy. Neoplasia. 2026;73:101280.","journal-title":"Neoplasia"},{"issue":"1","key":"764_CR124","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s13402-025-01157-3","volume":"49","author":"M Padelli","year":"2026","unstructured":"Padelli M, Desterke C, Devocelle A, Uzan G, Lemoine A, Giron-Michel J. The epigenetic regulator SETDB1 as a key component of cancer stem cells and drug resistance in primary liver cancer. Cell Oncol (Dordr). 2026;49(1):18.","journal-title":"Cell Oncol (Dordr)"},{"issue":"1","key":"764_CR125","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1038\/s41467-025-68156-8","volume":"17","author":"Y Pan","year":"2026","unstructured":"Pan Y, Zeng C, He Y, Chang R, Wu J, Yuan C, et al. Targeting SPAK suppresses progression and averts an immune exhaustive microenvironment in hepatocellular carcinoma. Nat Commun. 2026;17(1):1414.","journal-title":"Nat Commun"},{"issue":"11","key":"764_CR126","doi-asserted-by":"publisher","first-page":"7847","DOI":"10.21037\/tcr-2025-1463","volume":"14","author":"Q Wang","year":"2025","unstructured":"Wang Q, Ye Y, Zhang M, Li B. MCRS1 is associated with immunosuppressive microenvironments in pan-cancer and promotes hepatocellular carcinoma malignant phenotypes. Transl Cancer Res. 2025;14(11):7847\u201369.","journal-title":"Transl Cancer Res"},{"issue":"46","key":"764_CR127","doi-asserted-by":"publisher","first-page":"e11152","DOI":"10.1002\/advs.202511152","volume":"12","author":"B Gao","year":"2025","unstructured":"Gao B, Wang Y, Sun Z, Tang H, Cao Y, Jiang H, et al. NQO1\/p65\/CXCL12 Axis-Recruited Tregs Mediate Resistance to Anti-PD-1 Plus Lenvatinib Therapy in PIVKA-II-Positive Hepatocellular Carcinoma. Adv Sci (Weinh). 2025;12(46):e11152.","journal-title":"Adv Sci (Weinh)"},{"issue":"5","key":"764_CR128","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.21037\/jgo-2025-250","volume":"16","author":"W Yang","year":"2025","unstructured":"Yang W, Chen Y, Guo H, Zhang J, Wang S, Peng L. STRIP2 promotes hepatocellular carcinoma progression and immune evasion: a potential prognostic biomarker and therapeutic target. J Gastrointest Oncol. 2025;16(5):2314\u201335.","journal-title":"J Gastrointest Oncol"},{"key":"764_CR129","first-page":"0950","volume":"8","author":"Z Zhu","year":"2025","unstructured":"Zhu Z, Zhang K, Wu W, Zhou J, Zhang M, Chen J, et al., et al. POSTN(+) CAF-Derived Migrasomes Drive Hepatocellular Carcinoma Progression and Confer Resistance to Immunotherapy. Res (Wash D C). 2025;8:0950.","journal-title":"Res (Wash D C)"},{"key":"764_CR130","doi-asserted-by":"crossref","unstructured":"Xu W, Zhao Y, Weng J, Yu M, Yu Q, Xie P, et al. Galectin-4 drives anti-PD-L1\/BVZ resistance by regulating metabolic adaptation and tumour-associated neutrophils in hepatocellular carcinoma. Gut. 2025.","DOI":"10.1136\/gutjnl-2025-336374"},{"issue":"1","key":"764_CR131","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-025-02367-9","volume":"10","author":"Y Li","year":"2025","unstructured":"Li Y, Chen Z, Wang D, Du W, Zhu N, Shen X, et al. Transforming acidic coiled-coil-containing protein 3-mediated lipid metabolism reprogramming impairs CD8+ T-cell cytotoxicity in hepatocellular carcinoma. Signal Transduct Target Ther. 2025;10(1):274.","journal-title":"Signal Transduct Target Ther"},{"issue":"108","key":"764_CR132","doi-asserted-by":"publisher","first-page":"eado3485","DOI":"10.1126\/sciimmunol.ado3485","volume":"10","author":"J Liang","year":"2025","unstructured":"Liang J, Liao J, Chang R, Jia W, Li G, Chen Z, et al. Riplet promotes lipid metabolism changes associated with CD8 T cell exhaustion and anti-PD-1 resistance in hepatocellular carcinoma. Sci Immunol. 2025;10(108):eado3485.","journal-title":"Sci Immunol"},{"issue":"7","key":"764_CR133","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1158\/2159-8290.CD-22-1062","volume":"13","author":"O Goldman","year":"2023","unstructured":"Goldman O, Adler LN, Hajaj E, Croese T, Darzi N, Galai S, et al. Early Infiltration of Innate Immune Cells to the Liver Depletes HNF4\u03b1 and Promotes Extrahepatic Carcinogenesis. Cancer Discov. 2023;13(7):1616\u201335.","journal-title":"Cancer Discov"},{"issue":"1","key":"764_CR134","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13045-024-01549-2","volume":"17","author":"KY Shen","year":"2024","unstructured":"Shen KY, Zhu Y, Xie SZ, Qin LX. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives. J Hematol Oncol. 2024;17(1):25.","journal-title":"J Hematol Oncol"},{"key":"764_CR135","unstructured":"Wu F, Guo Z, Guan J, Xu J, Chen Y, Chen Z. IL-15 plus thymosin \u03b11 reduces senescent hepatic CD8+ T cells in hepatocellular carcinoma via PI3K\/AKT suppression. J Gastroenterol Hepatol. 2026."},{"issue":"1","key":"764_CR136","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12964-025-02162-7","volume":"23","author":"J Zhang","year":"2025","unstructured":"Zhang J, Li Z, Zhang Q, Ma W, Fan W, Dong J, et al. LAMA4(+) CD90(+) eCAFs provide immunosuppressive microenvironment for liver cancer through induction of CD8+ T cell senescence. Cell Commun Signal. 2025;23(1):203.","journal-title":"Cell Commun Signal"},{"issue":"12","key":"764_CR137","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1158\/0008-5472.CAN-24-3180","volume":"85","author":"Y Chang","year":"2025","unstructured":"Chang Y, Wang N, Li S, Zhang J, Rao Y, Xu Z, et al. SLC3A2-Mediated Lysine Uptake by Cancer Cells Restricts T-cell Activity in Hepatocellular Carcinoma. Cancer Res. 2025;85(12):2250\u201367.","journal-title":"Cancer Res"},{"key":"764_CR138","doi-asserted-by":"publisher","first-page":"111039","DOI":"10.1016\/j.cellsig.2024.111039","volume":"115","author":"B Pan","year":"2024","unstructured":"Pan B, Ke X, Qiu J, Ye D, Zhang Z, Zhang X, et al. LAIR1-mediated resistance of hepatocellular carcinoma cells to T cells through a GSK-3\u03b2\/\u03b2-catenin\/MYC\/PD-L1 pathway. Cell Signal. 2024;115:111039.","journal-title":"Cell Signal"},{"key":"764_CR139","doi-asserted-by":"publisher","first-page":"1710741","DOI":"10.3389\/fimmu.2025.1710741","volume":"16","author":"S Li","year":"2025","unstructured":"Li S, Ma J, Li X, Qiao B, Wang L, Li D, et al. Multi-omics spatial characteristics of CD8(+)TRM cells in hepatocellular carcinoma and immunotherapy response prediction. Front Immunol. 2025;16:1710741.","journal-title":"Front Immunol"},{"issue":"2","key":"764_CR140","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.jhep.2021.09.007","volume":"76","author":"F Foerster","year":"2022","unstructured":"Foerster F, Gairing SJ, M\u00fcller L, Galle PR. NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. J Hepatol. 2022;76(2):446\u201357.","journal-title":"J Hepatol"},{"key":"764_CR141","doi-asserted-by":"crossref","unstructured":"EASL. 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370\u2009\u2013\u200998.","DOI":"10.1016\/j.jhep.2017.03.021"},{"issue":"Suppl","key":"764_CR142","doi-asserted-by":"publisher","first-page":"S228","DOI":"10.3350\/cmh.2024.0824","volume":"31","author":"SY Hwang","year":"2025","unstructured":"Hwang SY, Danpanichkul P, Agopian V, Mehta N, Parikh ND, Abou-Alfa GK, et al. Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment. Clin Mol Hepatol. 2025;31(Suppl):S228\u201354.","journal-title":"Clin Mol Hepatol"},{"key":"764_CR143","doi-asserted-by":"publisher","first-page":"101210","DOI":"10.1016\/j.plipres.2022.101210","volume":"89","author":"S Lin","year":"2023","unstructured":"Lin S, Wang S, Wang P, Tang C, Wang Z, Chen L, et al. Bile acids and their receptors in regulation of gut health and diseases. Prog Lipid Res. 2023;89:101210.","journal-title":"Prog Lipid Res"},{"issue":"2","key":"764_CR144","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nrgastro.2017.119","volume":"15","author":"W Jia","year":"2018","unstructured":"Jia W, Xie G, Jia W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat Rev Gastroenterol Hepatol. 2018;15(2):111\u201328.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"764_CR145","doi-asserted-by":"publisher","first-page":"121459","DOI":"10.1016\/j.biomaterials.2022.121459","volume":"283","author":"B Kovacevic","year":"2022","unstructured":"Kovacevic B, Jones M, Ionescu C, Walker D, Wagle S, Chester J, et al. The emerging role of bile acids as critical components in nanotechnology and bioengineering: Pharmacology, formulation optimizers and hydrogel-biomaterial applications. Biomaterials. 2022;283:121459.","journal-title":"Biomaterials"},{"issue":"4","key":"764_CR146","doi-asserted-by":"publisher","first-page":"102038","DOI":"10.1016\/j.xcrm.2025.102038","volume":"6","author":"K Yasukawa","year":"2025","unstructured":"Yasukawa K, Shimada S, Akiyama Y, Taniai T, Igarashi Y, Tsukihara S, et al. ACVR2A attenuation impacts lactate production and hyperglycolytic conditions attracting regulatory T cells in hepatocellular carcinoma. Cell Rep Med. 2025;6(4):102038.","journal-title":"Cell Rep Med"},{"issue":"7","key":"764_CR147","doi-asserted-by":"publisher","first-page":"e00518","DOI":"10.1128\/msystems.00518-25","volume":"10","author":"Z Lu","year":"2025","unstructured":"Lu Z, Yu L, Bai Y, Cui Y, Shi M, Li Z, et al. The potential mechanisms of reciprocal regulation of gut microbiota-liver immune signaling in metabolic dysfunction-associated steatohepatitis revealed in multi-omics analysis. mSystems. 2025;10(7):e00518\u201325.","journal-title":"mSystems"},{"issue":"1","key":"764_CR148","doi-asserted-by":"publisher","first-page":"2302065","DOI":"10.1080\/19490976.2024.2302065","volume":"16","author":"J Xu","year":"2024","unstructured":"Xu J, Xia Q, Wu T, Shao Y, Wang Y, Jin N, et al. Prophylactic treatment with Bacteroides uniformis and Bifidobacterium bifidum counteracts hepatic NK cell immune tolerance in nonalcoholic steatohepatitis induced by high fat diet. Gut Microbes. 2024;16(1):2302065.","journal-title":"Gut Microbes"},{"key":"764_CR149","doi-asserted-by":"crossref","unstructured":"Laivacuma S, Oblate O, Derovs A. Gut microbiota and the gut-liver axis in liver disease: from chronic viral hepatitis to cirrhosis, hepatocellular carcinoma, and microbiome-based therapies. Microorganisms. 2025;13(5).","DOI":"10.3390\/microorganisms13051053"},{"issue":"8083","key":"764_CR150","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41586-025-09395-z","volume":"646","author":"C Llorente","year":"2025","unstructured":"Llorente C, Raya Tonetti F, Bruellman R, Brea R, Pell N, Hartmann P, et al. mAChR4 suppresses liver disease via GAP-induced antimicrobial immunity. Nature. 2025;646(8083):180\u20139.","journal-title":"Nature"}],"container-title":["Infectious Agents and Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13027-026-00764-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13027-026-00764-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13027-026-00764-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:52:22Z","timestamp":1781650342000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13027-026-00764-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":150,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["764"],"URL":"https:\/\/doi.org\/10.1186\/s13027-026-00764-5","relation":{},"ISSN":["1750-9378"],"issn-type":[{"value":"1750-9378","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}